Long-Term Progression-Free Survival With Sunitinib in Advanced Recurrent Adrenocortical Carcinoma.

IF 2.5 4区医学 Q2 PHARMACOLOGY & PHARMACY

American journal of therapeutics Pub Date : 2025-04-11 DOI:10.1097/MJT.0000000000001943

Ali Turker, Mahmut Buyuksimsek, İrem Kolsuz Turker, Mehmet Turker, İrfan Alisan

引用次数: 0

查看原文本刊更多论文

舒尼替尼治疗晚期复发性肾上腺皮质癌的长期无进展生存率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

American journal of therapeutics PHARMACOLOGY & PHARMACY-

CiteScore

5.50

自引率

9.50%

发文量

142

审稿时长

6-12 weeks

期刊介绍： American Journal of Therapeutics is an indispensable resource for all prescribing physicians who want to access pharmacological developments in cardiology, infectious disease, oncology, anesthesiology, nephrology, toxicology, and psychotropics without having to sift through stacks of medical journals. The journal features original articles on the latest therapeutic approaches as well as critical articles on the drug approval process and therapeutic reviews covering pharmacokinetics, regulatory affairs, pediatric clinical pharmacology, hypertension, metabolism, and drug delivery systems.